Tolerability of Fluoroquinolones in Management of Latent Tuberculosis in Liver Transplant Candidates: Table 1.

Tien, Vivian; Robilotti, Elizabeth; Callister, Devin; Subramanian, Aruna; Lutchman, Glen; Ho, Dora Y.

doi:10.1093/cid/civ639

Cited by 14 publications

(15 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our extensive review of the literature identified four other detailed case reports that documented the development of active TB disease after LTBI treatment . In addition, we found a total of 56/2651 (2.1%) cases of active TB among 41 observational cohorts and six RCT . Among them, only five cases were described in detail.…”

Section: Resultsmentioning

confidence: 95%

“…We found 41 cohort studies that evaluated the outcome of LTBI therapy. Eleven were from Europe, 10 from US and Asia, seven from South America, and one each from Africa, Australia, and Canada . Only nine were prospective .…”

Section: Resultsmentioning

confidence: 99%

“…Only nine were prospective . Most studies included kidney (22) and liver (12) transplant recipients only. There were three studies on lung and four on multiple organ transplants .…”

Section: Resultsmentioning

confidence: 99%

“…The indication was not specified in two studies . Fifteen studies initiated prophylaxis based on TST or IGRA responses alone. INH prophylaxis was the preferred regimen in all studies except one, which used a combination of levofloxacin and ethambutol .…”

Section: Resultsmentioning

confidence: 99%

“…INH prophylaxis was the preferred regimen in all studies except one, which used a combination of levofloxacin and ethambutol . Alternative regimens included RIF, quinolones INH/RIF, or others . The length of prophylaxis ranged from 1 to 18 months, but was not specified in six studies .…”

Section: Resultsmentioning

confidence: 99%

See 4 more Smart Citations

Treatment of latent TB Infection and the risk of tuberculosis after solid organ transplantation: Comprehensive review

Abad

Deziel

Razonable

2019

Transplant Infectious Dis

View full text Add to dashboard Cite

Background: Mycobacterium tuberculosis disease may occur after treatment of latent TB infection (LTBI). Prompted by a case of reactivation TB disease in a solid organ transplant (SOT) recipient who received LTBI treatment, we reviewed the literature to examine outcomes, adverse effects, resistance, and treatment choices of tuberculosis after LTBI therapy.Methods: MEDLINE and Web of Science from inception to 5/2019 were reviewed using key words "latent tuberculosis infection" and "SOT" or "transplantation." The search yielded nine cases, 41 cohort studies and six randomized controlled trials (RCT). Results: Cohort and RCT demonstrated significant reduction in TB disease among transplanted patients who received LTBI therapy; only 56/2651 (2.1%) SOT patients developed TB after LTBI therapy. Adverse drug reactions occurred in 149/1148 (12.9%) and 73/641 (11.4%) of cohort and RCT patients, respectively. Among liver recipients, 56/266 (21%) developed side effects, of which half (29/56, 51.8%) was INH-related. There was no reported INH resistance. Conclusions: Latent TB infection treatment is efficacious in SOT recipients at risk of TB disease. However, tuberculosis may still occur despite LTBI treatment. Hepatotoxicity associated with LTBI therapy is infrequent, although more commonly observed among liver recipients. K E Y W O R D S latent TB, Mycobacterium tuberculosis, solid organ transplant

show abstract

Section: Resultsmentioning

confidence: 95%

Section: Resultsmentioning

confidence: 99%

“…Only nine were prospective . Most studies included kidney (22) and liver (12) transplant recipients only. There were three studies on lung and four on multiple organ transplants .…”

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

See 3 more Smart Citations

Treatment of latent TB Infection and the risk of tuberculosis after solid organ transplantation: Comprehensive review

Abad

Deziel

Razonable

2019

Transplant Infectious Dis

View full text Add to dashboard Cite

show abstract

Experience With Moxifloxacin for the Treatment of Latent Tuberculosis Infection in Liver Transplantation: A Single‐Center Prospective Study

et al. 2021

View full text Add to dashboard Cite

Current guidelines recommend the treatment of latent tuberculosis infection (LTBI) among liver transplantation (LT) candidates with compensated cirrhosis, with isoniazid plus pyridoxine as the preferred regimen. (1)(2)(3) Nevertheless, completion rates and tolerability are low. Fluoroquinolones (FQs) exhibit good antimycobacterial activity and a favorable safety profile and could serve as an alternative to isoniazid. To provide further insight into the role of FQs for this indication, we report our experience with a 9-month moxifloxacin regimen for the treatment of LTBI in the LT setting. Patients and MethodsSince November 2015, the use of moxifloxacin (400 mg daily) for 9 months, preferably implemented while patients are on the waiting list, has replaced isoniazid or rifampicin for the treatment of LTBI in LT candidates and recipients in our center. If pretransplant treatment was not feasible, moxifloxacin was initiated once graft function was normalized. The study was primarily aimed at evaluating the safety and tolerability of the 9-month moxifloxacin regimen, whereas the occurrence of active tuberculosis (TB) upon completion of LTBI therapy was analyzed as the secondary outcome. Details on institutional protocols, definitions, patient follow-up, and statistical methods are available as Supporting Information. ResultsOverall, 38 patients (28 LT candidates and 10 LT recipients) received moxifloxacin for LTBI between December 2015 and November 2019 (Supporting Table 1). A total of 2 patients with no history of liver disease had previously developed isoniazid-induced acute liver failure while on LTBI therapy.The median duration of moxifloxacin treatment was 260 days (interquartile range [IQR], 180-274). Of 28 candidates, 17 (60.7%) underwent transplantation while on LTBI therapy at a median interval of 103 days (IQR, 53-167) from the initiation of moxifloxacin.

show abstract

Safety and outcome of treatment of latent tuberculosis infection in liver transplant recipients

Lee,

Chung,

Kim

et al. 2024

Infection

View full text Add to dashboard Cite

Tolerability of Fluoroquinolones in Management of Latent Tuberculosis in Liver Transplant Candidates: Table 1.

Cited by 14 publications

References 3 publications

Treatment of latent TB Infection and the risk of tuberculosis after solid organ transplantation: Comprehensive review

Treatment of latent TB Infection and the risk of tuberculosis after solid organ transplantation: Comprehensive review

Experience With Moxifloxacin for the Treatment of Latent Tuberculosis Infection in Liver Transplantation: A Single‐Center Prospective Study

Safety and outcome of treatment of latent tuberculosis infection in liver transplant recipients

Contact Info

Product

Resources

About